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Abstract   
 
When cellular contractile forces are central to pathophysiology, these forces comprise a logical target 
of therapy.  Nevertheless, existing high-throughput screens are limited to upstream signaling 
intermediates with poorly defined relationship to such a physiological endpoint.  Using cellular force 
as the target, here we screened libraries to identify novel drug candidates in the case of human airway 
smooth muscle cells in the context of asthma, and also in the case of Schlemm’s canal endothelial 
cells in the context of glaucoma.  This approach identified several drug candidates for both asthma 
and glaucoma. We attained rates of 1000 compounds per screening day, thus establishing a force-
based cellular platform for high-throughput drug discovery.  
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Main Text 
In many organs and tissues, cellular contractile forces play a central role in physiology and 
pathophysiology.  As such, modulation of cellular contractile forces is often the main therapeutic strategy.  
Commonplace examples are cardiac inotropes for cardiomyocytes (1), bronchodilators for airway smooth 
muscle cells (2), vasodilators for vascular smooth muscle cells (3), and relaxants for skeletal muscle cells (4).  
Cellular contractile forces are also important in metastasis and cancer cell invasion (5, 6).  In each of these 
instances there clearly exist urgent unmet therapeutic needs (7-9).  Nevertheless, it has not previously been 
practical to use measurements of cellular contractile forces themselves as a primary read-out in high-
throughput drug discovery.  Instead, currently available high-throughput screening technologies have been 
limited to measurements of surrogates for contraction itself, including upstream effectors such as intracellular 
messengers, binding affinity assays against specific cell surface receptors or other moieties, protein 
expression and protein relocation, or morphological changes (10-13).  
 
The strength of these existing high-throughput approaches is that they are remarkably fast, but the 
weakness is that they stop short of incorporating and directly evaluating the main therapeutic target – cellular 
contractile force.  Depending upon the assay, therefore, not only are certain drug candidates potentially missed, 
but also many of the corresponding hits might be found subsequently to have little or no impact on contractile 
force.  Necessarily, efficacy and validation of these hits can only be established independently using old-
fashioned low throughput methods such as contractility measured in the isolated muscle strip (14) or reactivity 
measured in the living organism (15).  Cellular deformability  has been proposed as a high-throughput basis for 
cell screening in the context of cancer (16), malaria (17) and malignant pleural effusions (18) but these assays 
are limited to floating cells and are insensitive to depolymerization of actin, inhibition of myosin (19), or 
modulation of adhesion proteins.  In anchorage-dependent cells, and especially when contractile force is of 
concern, such assays are inapplicable.  In the context of physiological and organ systems modeling, in-vitro 
tissue constructs and organ-on-chip technologies are also promising (20-22) but, compared to the approach 
described below, are considerably more complex and thus less well suited for high levels of screening 
throughput.  Overall, many potential drugs have been found via current high-throughput assays, but the 
majority of new molecular entities approved by US Food and Drug Administration (FDA) continue to be 
discovered via traditional phenotypic assays (23).  Moreover, because 50% of drug candidates currently fail in 
phase II clinical trials (24), it has been suggested that decreased failure rates and reduced development costs 
might be attained if disease-relevant endpoints were brought into drug discovery at an earlier stage (25).  To fill 
this gap, we describe here a simple new assay based upon straightforward measurement of cellular contractile 
force itself, which serves as the targeted physiological endpoint. 
 
Contractile force screening (CFS) is based upon Fourier-transform traction microscopy (26-29), which we 
adapted to 96-well plates (30).  In each well, polyacrylamide gel surfaces were labeled with fluorescent 
markers (31), functionalized with collagen (32), and covered with cells grown to near confluence (27-29, 33) 
(Fig. 1A-B, Supplementary Fig. 1).  Using an automated fluorescence microscope, we quantified in each well 
the average (i.e. root mean square) cellular contractile forces before and after adding drugs.  Drug effects were 
quantified as the ‘force response ratio’, namely, the contractile force before versus after drug addition (Fig. 1C).  
For example, the average contractile force generated by cultured primary human airway smooth muscle 
(HASM) cells at baseline was 38 Pa (left column in Fig. 1C), and force did not change after adding vehicle 
alone (dimethyl sulfoxide (DMSO), 0.5%, final concentration); thus, the force response ratio for vehicle was 
close to 1.  The force response ratio for fetal bovine serum (FBS, 1%), which is known to increase contraction 
(34), was 1.77 (middle column in Fig. 1C), while that for the rho kinase inhibitor Y27632 (10 µM)(35), known to 
impair contraction, was 0.29 (right column in Fig. 1C).  Force response ratios revealed dose-dependent 
increases or decreases in cellular contractile force induced by FBS (Fig. 1D), Y27632, and the airway smooth 
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muscle cell relaxant isoproterenol (Fig. 1E).  Furthermore, using these force response ratios, CFS 
demonstrated that the robust Z’-factor was bigger than 0.6 (methods; Supplementary Fig. 3), thus confirming 
that the force response ratio provides a methodologically simple, physiologically relevant, and statistically valid 
index for identifying compounds that modulate cellular contractile forces.  
 
To test the utility of CFS in the context of drug repurposing for use in asthma, we focused upon HASM cells.  
During an acute asthma attack, contractile forces generated by HASM cells act to constrict the airway and thus 
obstruct airflow.  To dilate constricted airways, asthma patients use bronchodilators to reduce these contractile 
forces and thus allow the airway to open more fully, but currently available bronchodilator medications often fail 
to relax that muscle sufficiently, especially in severe asthma (2).  To address this unmet need for more 
effective bronchodilator medications, we screened the Prestwick Chemical Library®, comprised of 1,120 drugs 
already approved by the FDA or European Medicines Agency (EMA), to identify which among these might be 
an unanticipated candidate to relax airway smooth muscle cells in asthma.  Each datum plotted represents the 
average of quadruplicate measurements of a mixture of 4 drugs/well, with a concentration of 6.5µM for each in 
the initial screen (Fig. 2A, left panel); the middle panel is the histogram of all responses and the right panel is 
the rank-ordered response.  Mixtures that modulated contractile force appreciably – termed positives – were 
later retested individually to identify the active drugs – termed hits.  Most mixtures did not change cellular 
contractile forces appreciably.  Several mixtures increased the force response ratio more than did FBS, and, 
more importantly, several mixtures decreased the response ratio as much as or more than control relaxant 
compounds.  From 280 mixtures tested, we selected 15 mixtures as positives (shown in red in Fig. 2A) that 
were found to blunt contractile force appreciably.  After retesting drugs individually, we found 15 hits; 9 were -
adrenergic receptor agonists and 3 (alprostadil (36, 37), ethaverine hydrochloride (38) and kaempferol (39, 40)) 
were already well-known as smooth muscle relaxants (Supplementary Table 1A).  However, the HASM 
relaxant effects of three drugs were unexpected: Chicago sky blue, terconazole and levonordefrin (α-
methylnorepinephrine).  These findings confirm the ability of CFS to identify novel relaxants of airway smooth 
muscle. 
   
To validate further the utility of CFS in a different disease context, we turned to human endothelial cells of 
Schlemm’s canal (SC) in the context of drug repurposing for use in glaucoma, which remains a leading cause 
of blindness (41).  All current drug treatments and surgical treatments for glaucoma target reduction of 
intraocular pressure, but many patients remain refractory to those treatments.  Because excessive contraction 
of the SC cell has been implicated recently in the etiology of glaucoma (42, 43), we first tested human SC cells 
using the control drugs described above and found that they modulated contractile force of SC cells much as 
they did in HASM cells (Fig. 1F).  Next, from the Prestwick Chemical Library®, 17 individual drugs were 
identified as hits that blunted SC cell contraction.  One was a toxin (Sanguinarine), 9 were -adrenergic 
receptor agonists already well-known as SC relaxants, and one was a vasodilator (Alprostadil, Supplementary 
Table 1B).  Alprostadil was the most potent of these hits; further inspection revealed that alprostadil reduced 
contractile force of SC cells in a dose-dependent manner (supplementary Fig. 4A) and its efficacy was further 
validated in perfusion studies testing aqueous humor outflow function in enucleated mouse eyes 
(Supplementary Fig. 4B). 
  
Having established the feasibility of using CFS in a small library like the Prestwick Chemical Library®, we 
turned next to larger libraries and questions of throughput.  In a subset comprising 10,000 compounds selected 
randomly from the Chembridge DIVERset®, we set up each drug plate to contain 35 different compound 
mixtures and 5 controls, with each mixture consisting of 8 compounds.  Since hits are few (Fig. 2), the 
probability of interactions between compounds or cancelling effects in any given well is small.  For this 
screening, we used HASM cells to find novel candidate bronchodilators.  With drug incubation time of 1 hr and 
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using a single microscope, we screened all 10,000 compounds at the rate of 1,120 compounds per screening 
day (Supplementary Fig. 5).  From this screen, we found 12 positives (Fig. 2B) and finally 2 hits that were 
closely related structurally.  Further studies of these compounds revealed that contractile forces in HASM cells 
were reduced substantially, non-toxically, and in a dose-dependent manner (Supplementary Fig. 6).  
 
In summary, Contractile Force Screening is a high throughput technology that directly addresses the 
physiologic target of interest, with an overall throughput on the order of at least a thousand compounds per 
microscope per day.  Because this study did not employ automation or robotic handing, substantially higher 
levels of throughput should be readily attainable.  CFS can thus fill an important methodological void in the 
middle ground between high-throughput but relatively non-physiological approaches on the one hand and 
physiological but low-throughput animal or tissue-based approaches on the other.  As such, CFS has the 
potential to facilitate drug discovery and drug repurposing in any circumstance in which modulation of 
contractile force is the logical therapeutic target, including vascular and cardiac disease, pulmonary arterial 
hypertension, asthma, glaucoma, and metastatic and invasive disease. 
  
 
Methods:   
Cell culture: Primary human airway smooth muscle (HASM) cells were obtained from lungs unsuitable for 
transplantation, as previously described (32, 44).  Passage 5-7 cells from 5 donors were used for assay 
development.  Screening and secondary validations of both the Prestwick® and Chembridge DIVERset® 
libraries were restricted to passage 7 cells from one donor.  10,000 cells per well were seeded onto assay 
plates in a medium containing 10% fetal bovine serum (FBS).  After 2 hours of incubation, the serum 
containing medium was replaced with serum free medium containing insulin (5.7µg/mL) and transferrin 
(5µg/mL) instead of FBS for an additional 48 hour prior to experimentation. 
 
Human endothelial cells of the inner wall of Schlemm’s canal (SC) were obtained from post-mortem human 
eyes provided by Midwest Eye Bank, NDRI or Life Legacy as previously described (43, 45); passage 6-7 from 
1 donor were used.  Approximately 3,200 to 6,400 cells per well were seeded onto assay plates in a medium 
containing 1% FBS.  Cells were grown in this medium for 2 days and in serum free medium supplemented with 
insulin-transferrin-selenium for an additional 12 hours prior to experimentation. 
 
Preparation of drug mixtures: From the Prestwick Chemical Library®, we screened 1,120 drugs.  4 drugs 
within the same column of the source plate were mixed together and distributed within drug plates as shown in 
Supplementary Figure 2.  From the Chembridge DIVERSet Library®, we screened 10,000 compounds.  8 drugs 
within same column in the source plates were mixed together and distributed within drug plates as shown in 
Supplementary Figure 2.   
Perfusion of mouse eyes: Perfusions were performed in enucleated eyes obtained from 11 C57BL/6 mice of 
either gender, aged 10 weeks to 7 months old at time of death.  Enucleated eyes were stored in phosphate 
buffered saline at 4°C until perfusion, typically 1-3 hours.  The perfusion method follows previously described 
techniques that we developed (46-50) with a few modifications.  Briefly, each enucleated eye was affixed onto 
a post using cyanoacrylate glue; stabilizing the eye for cannulation of the anterior chamber.  Eyes were 
cannulated with a 33-gauge beveled-tip needle (Nanofil; World Precision Instruments, Europe; Hitchin, UK) 
backfilled with 1 M alprostadil or vehicle (ethanol, 1: 10,000).  Housed in a humidified chamber, eyes were 
perfused in pairs and randomized for each perfusion as to whether drug or vehicle was perfused first.  The 
needle was connected via pressure tubing to a glass syringe (25 µL; Hamilton GasTight, Reno, NV) that was 
mounted and controlled by motorized syringe pump (PHD Ultra; Harvard Apparatus, MA).  Custom written 
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LabVIEW software (National Instruments Corp., Austin, TX) served to monitor intraocular pressure (IOP) (via in 
line 142PC01G pressure transducer; Honeywell, Columbus, OH) and control the flow rates delivered by the 
syringe pump into the eye to maintain a user-defined IOP (13).  Both experimental and control eyes were 
initially held at 8mmHg for 45 minutes using a fluid reservoir to facilitate exposure of cells in the outflow 
pathway to drug (or vehicle).   Subsequently, eyes were perfused at sequential pressure steps of 4, 8, 15 and 
20 mmHg.  Each pressure step was maintained for 20-30 minutes to obtain a minimum of 10 minutes of stable 
flow data, from which an average stable flow rate was calculated for each pressure step.  Data from an 
individual eye was considered acceptable if a stable flow rate was achieved in at least 3 of the 4 pressure 
steps.  Outflow facility was found following the general principle of the two-level constant pressure perfusion 
procedure introduced by Barany (51). Here we measured flow rate (Q) at four pressures (P), and then found 
the outflow facility using a regression analysis by fitting the data to the following relationship using SPSS: 
 
𝑄 =  𝑎0  +  𝑎1 ∗ 𝑃 +  𝑎2 ∗ 𝑃 ∗  𝐷𝑅𝑈𝐺 
 
where DRUG=0 is the control case and DRUG=1 when alprostadil was applied. a1 is the outflow facility for 
control eyes and a1 + a2 that for eyes after alprostadil application. 
 
Preparation of deformable substrates in 96-well plates: Polyacrylamide based gel substrates were 
miniaturized in glass bottom 96-well plates using one of two methodologies.  In the first method, each 96-well 
plate was treated with NaOH (6N in water) for 1hr followed by silane solution ((3-aminopropyl)trimethoxysilane, 
10% in water) for an additional 1hr.  Next, red fluorescent bead solution (1µm carboxylate-modified 
microspheres, Invitrogen, 2x10-4% in water) was added to the wells and air-dried overnight.  Dried glass 
surfaces were then treated with glutaraldehyde (0.25% in PBS) for 30min and further washed and dried.  
Acrylamide gels (5.5% acrylamide, 0.076% bisacrylamide, Young’s modulus = 1.8kPa, thickness = 200 µm) 
were cast in each well using a custom-made gel caster (30) (Matrigen Life Technologies, CA).  The gel 
surfaces were functionalized using sulfo-SANPAH (sulfosuccinimidyl-6-[4´-azido-2´-
nitrophenylamino]hexanoate, 0.2mg/mL), coated with green beads (0.2µm sulfate microspheres, Invitrogen, 
2x10-3% in water) (31), coated with bovine collagen I (40µg/mL in PBS) (32) and were stored at 4C (Fig. 1A).  
 
In the second method, each 96-well plate was treated with silane (γ-methacryloxypropyltrimethoxysilane, 0.4% 
in water), and a first layer of acrylamide gel substrate (8% acrylamide, 0.1% bisacrylamide, and 0.4% acrylic 
acid N-hydroxysuccinimide ester (NHS)(52), Young’s modulus ≈ 2.5 kPa, thickness ≈ 200 µm) was prepared 
using the custom-made gel caster described above. The casting procedure was repeated for a second layer of 
gel (53) with the same composition plus 2% vol/vol red beads (0.5µm carboxylate-modified microspheres, 
Invitrogen); this top layer was prepared exceedingly thin to promote fluorescent bead dispersion within a single 
horizontal plane.  The gels were coated with bovine collagen I (10 µg/mL in PBS) (Supplementary Fig. 1). 
  
Measurements of contractile forces using Fourier-transform traction microscopy: The 96-well plate was 
mounted within a heated chamber (37C) upon a motorized stage and imaged using an inverted microscope 
(DMI 6000B, Leica Inc.).  In each well, three images were obtained in quick succession: one phase contrast 
image of cells and a pair of fluorescent images of beads (Fig 1A).  The image set was obtained before plating 
cells (reference), immediately prior to adding drugs (baseline), and 1 hr after drug addition (treatment).  By 
comparing fluorescent images obtained during baseline or treatment with the corresponding image from 
reference, we computed the cell-exerted displacement field (26, 27).  From the displacement field, we 
computed the contractile force (per unit area) using Fourier-transform traction microscopy (26, 27) modified to 
the case of cell monolayers (27-29, 52).  This modified approach takes into consideration effects of finite gel 
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thickness as well as force imbalances associated with the microscope field of view as we described previously 
(27, 28).  From each force map (Fig 1B), we computed the root mean squared value to represent the averaged 
contractile force. Throughout the paper, we use the generic word “force” to mean the traction which is the 
contractile force (per unit area) that cells exert on their substrate.   
 
Evaluation of CFS:   Traditional Z’-factor (54) has been widely used as a quality metric for small-molecule 
screens but it has limitations such as its sensitivity on data distribution or outliers (55).  Therefore alternative 
metrics have been suggested including the robust Z’-factor (56).  The variability of cellular stiffness and 
contractile force in HASM cells are known to be very high (57, 58) and the distribution of the force response 
ratios are closer to a log-normal distribution (Fig. 2).  Hence, we used here the robust Z’-factor as a quality 
metric of CFS.  The robust Z’-factor is defined as below: 
𝑟𝑜𝑏𝑢𝑠𝑡 𝑍′ = 1 −
3(𝑆1 + 𝑆2)
|𝑋1 − 𝑋2|
 
where, S1 and S2 are the median absolute deviations of negative and positive controls and X1 and X2 are the 
medians of negative and positive controls.  We used vehicle control (water, 0.01%) as the negative control and 
rho-kinase inhibitor, Y27632 (12µM) as the positive control.  The control compounds were distributed equally in 
the 96 well-plate and examined for their effects on cellular contractile forces.  From these measurements, we 
computed the robust Z’-factor and it was 0.605 (Supplementary Fig. 3). 
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Figure Legends 
Figure 1: Contractile force screening (CFS). (A) Acrylamide-based hydrogels were miniaturized in glass 
bottom 96-well plates.  (B) In each well, three images were obtained in quick succession: one phase contrast 
image of cells and a pair of fluorescent images of beads.  (C) Maps of cellular contractile force (per unit area) 
before (top) and 1 hr after addition of drugs (bottom) together with the average magnitude indicated in the 
lower-left corner.  Drug effects were quantified as the force response ratio, namely, the average contractile 
force before versus after drug addition.  The dose-dependent force response ratio of (D-E) human airway 
smooth muscle (HASM) cells, and, (F) Schlemm’s canal (SC) endothelial cells.  Plotted in D and E are the 
average values ± SD and in F the average values ± SEM.  
 
Figure 2: CFS for novel bronchodilatory drugs. (A) Each datum corresponds to the force response ratio for 
each mixture from (A) the Prestwick® chemical library, or, (B) the Chembridge DIVERset® library.  Using the 
green dotted line as a cut-off, we selected for further evaluation the mixtures with the greatest relaxant effect, 
shown as red vertical lines.  Shown on the far right in the left panel are the response ratio for 4 controls; DMSO, 
FBS, isoproterenol, and Y27632.  The middle panel is the histogram with corresponding cut-off line and the 
right panel is the rank-ordered response.  A few mixtures in top ranks were disregarded based on variability 
within quadruplicate measurements.   
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Figure 2 
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Supplementary Figure 1: Preparation of deformable substrates in 96-well plates; an alternative method.  
Acrylamide-based hydrogels (Young’s modulus ≈ 2.5kPa, thickness ≈ 200µm) were miniaturized in glass 
bottom 96-well plates using a multi-layered approach.  Both layers had the same chemical composition with 
the exception of 2% wt/vol of red beads (0.5µm carboxylate-modified microspheres, Invitrogen) added to the 
top layer.  The top layer was prepared exceedingly thin to promote bead dispersion within a single horizontal 
plane.  
  
 
 
 
Supplementary Figure 2: Layout of drug plate. Each plate contained 35 different mixtures (1 to 35), vehicle 
control (0.5% DMSO), and three control drugs (1%FBS, 10μM or 25μM isoproterenol, and 10μM or 25μM 
Y27632).  
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Supplementary Figure 3: Force response ratio is a high-quality screening endpoint.  We assessed the 
high-throughput screening quality of CFS using the robust Z’-factor value (55, 56).  The value was found to be 
0.605 which exceeds the recommended value of 0.4 for a good quality HTS screen (59).  
 
 
 
Supplementary Figure 4: Alprostadil (prostaglandin E1) relaxes SC cells and promotes outflow 
function in enucleated mouse eyes. (A) Alprostadil reduced SC contractile forces in a dose dependent 
fashion with greater potency than isoproterenol at a concentration less than 10µM. (B) 1µM alprostadil 
increased outflow facility (inverse of flow resistance) during perfusion of enucleated mouse eyes. (p < 2x10-5, 
n=11 pairs). Plotted are the average ± SEM.     
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Supplementary Figure 5: High-throughput implementation of CFS. Using the Chembridge Diverset® library, 
we confirmed CFS throughput by screening 10,000 compounds within 4 weeks.  The estimation is based on 
96-well based assay plates, quadruplicate measurements, and 1hr drug incubation. 
 
 
 
 
Supplementary Figure 6: Secondary validation for novel bronchodilator hits identified by CFS. (A) The 
2 hits found from the Chembridge Diverset® did not affect cell viability depicted as the fluorescence intensity 
measured using a standard alamar Blue® assay (n=8 wells per compound per dose; 1% triton-X and 0.5% 
DMSO were used as negative and vehicle controls, respectively).  (B) Both hit compounds reduced cellular 
contractile force in a dose dependent manner (n=8 wells per compound per dose). Plotted are the average ± 
SD.   
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Supplementary Table 1: (A) From the screening of the Prestwick library, we identified 15 individual drugs that 
relaxed HASM cells.  (B) From the screening of the Prestwick library, we identified 17 individual drugs that 
relaxed SC cells. 
  
Supplementary Table 1A:  
Chemical name Effects 
Salbutamol 
β2-adrenergic receptor agonist 
Fenoterol hydrobromide 
Terbutaline hemisulfate 
Clenbuterol hydrochloride 
Ritodrine hydrochloride 
Metaproterenol sulfate 
Isoetharine mesylate salt 
(+)-Isoproterenol (+)-bitartrate salt 
(-)-Isoproterenol hydrochloride 
Alprostadil 
Known smooth muscle relaxant Ethaverine hydrochloride 
Kaempferol 
Chicago sky blue 6B Inhibitor of L-glutamate uptake 
Terconazole Anti-fungal medication 
Levonordefrin Vasoconstrictor 
 
Supplementary Table 1B: 
 
 
 
Chemical name Effects 
Salbutamol 
β2-adrenergic receptor agonist 
Fenoterol hydrobromide 
Terbutaline hemisulfate 
Clenbuterol hydrochloride 
Ritodrine hydrochloride 
Metaproterenol sulfate 
Isoetharine mesylate salt 
(+)-Isoproterenol (+)-bitartrate salt 
(-)-Isoproterenol hydrochloride 
Pepstatin A 
Inhibitor of aspartyl proteases, 
inhibits phosphorylation of ERK 
Cyclosporin A 
Immunosuppressant drug in 
organ transplantation 
Clioquinol 
Antifungal drug and 
antiprotozoal drug 
Chicago sky blue 6B Inhibitor of L-glutamate uptake 
Terconazole Anti-fungal medication 
Levonordefrin 
Topical nasal decongestant 
and vasoconstrictor in dentistry 
Sanguinarine Toxin 
Alprostadil 
Prostaglandin E1, known 
bronchodilator and vasodilator 
